The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

Outrage against PBMs was on full display when 400 pharmacy professionals in Kansas shuttered their businesses and petitioned ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

A giant healthcare company is suing the State of Minnesota over a state law that is supposed to protect small pharmacies in ...

Iowa pharmacists and advocates said Wednesday lawmakers need to pass legislation regulating pharmacy benefit managers, in ...